News | Stents | March 24, 2016

NIRTRAKS Study of Novel Coronary Stent Enrolls First Patient

Data will be collected from 131 patients across eight U.S. sites

Medinol, NIRTRAKS Study, NIRxcell Stent System, first patient

Image courtesy of Medinol

March 24, 2016 — Medinol announced the enrollment of their first patient in the U.S. NIRTRAKS Study. NIRTRAKS is a post marketing, non-randomized study of the NIRxcell Stent System in patients with coronary artery disease indicated for percutaneous coronary intervention (PCI). 

The study objective is to collect and analyze additional information about the safety and effectiveness of the NIRxcell stent in the treatment of de novo lesions in native coronary arteries in the U.S. population. The data will be collected from 131 patients with a primary endpoint of target vessel failure (TVF) at three years.  Manesh Patel, M.D., Duke University Hospital, is the national principal investigator (PI) for the study with a total of eight sites participating across the United States.  

"We are pleased with the start of the NIRTRAKS study, allowing us to gather further data on this unique and highly innovative technology.  While we have been utilizing the NIRxcell commercially for the last nine months, we are excited to further understand the clinical application this new design has for our patients," said Patel.

The first patient was enrolled into the study on Jan. 15, and over the last few weeks, site enrollment has continued to increase.

The NIRTRAKS study will look to build on the results of the PIONIR prospective study, which saw the NIRxcell stent demonstrate a 5.1 percent target lesion revascularization (TLR) rate at nine months, according to Medinol’s Chief Scientific Officer Yoram Richter, Ph.D.

The NIRxcell Stent is Medinol's fifth-generation coronary stent. It features the WiZeCell stent design, offering an optimal balance between vessel conformability, scaffolding integrity and radial strength.  The Flexx2 delivery system with a spring tip ensures ease of delivery even in the most tortuous and calcified anatomies.  NIRxcell became commercially available in the United States in January 2015.

NIRxcell Stent technology serves as a platform for Medinol's eDES (elastomer drug-eluting stent) currently in clinical trials in the U.S., Canada, Europe and Israel.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init